Fate Therapeutics Inc (NASDAQ: FATE) kicked off on Friday, down -5.19% from the previous trading day, before settling in for the closing price of $1.35. Over the past 52 weeks, FATE has traded in a range of $0.66-$5.92.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 46.37% over the past five years. While this was happening, its average annual earnings per share was recorded 7.36%. With a float of $103.49 million, this company’s outstanding shares have now reached $113.93 million.
Let’s look at the performance matrix of the company that is accounted for 181 employees. In terms of profitability, gross margin is -189.23%, operating margin of -1542.63%, and the pretax margin is -1366.46%.
Fate Therapeutics Inc (FATE) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Fate Therapeutics Inc is 9.70%, while institutional ownership is 84.88%. The most recent insider transaction that took place on Mar 06 ’25, was worth 104,881. Before that another transaction happened on Jan 10 ’25, when Company’s insider sold 5,980 for $1.55, making the entire transaction worth $9,269. This insider now owns 270,203 shares in total.
Fate Therapeutics Inc (FATE) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.38 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.36% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.78% during the next five years compared to -2.63% drop over the previous five years of trading.
Fate Therapeutics Inc (NASDAQ: FATE) Trading Performance Indicators
Take a look at Fate Therapeutics Inc’s (FATE) current performance indicators. Last quarter, stock had a quick ratio of 7.58. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.65, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -1.40 in one year’s time.
Technical Analysis of Fate Therapeutics Inc (FATE)
Fate Therapeutics Inc (NASDAQ: FATE) saw its 5-day average volume 2.87 million, a positive change from its year-to-date volume of 2.36 million. As of the previous 9 days, the stock’s Stochastic %D was 72.86%. Additionally, its Average True Range was 0.14.
During the past 100 days, Fate Therapeutics Inc’s (FATE) raw stochastic average was set at 22.35%, which indicates a significant decrease from 74.07% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 145.09% in the past 14 days, which was higher than the 111.90% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0584, while its 200-day Moving Average is $2.4161. Nevertheless, the first resistance level for the watch stands at $1.3300 in the near term. At $1.3800, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.4100. If the price goes on to break the first support level at $1.2500, it is likely to go to the next support level at $1.2200. Assuming the price breaks the second support level, the third support level stands at $1.1700.
Fate Therapeutics Inc (NASDAQ: FATE) Key Stats
The company with the Market Capitalisation of 146.69 million has total of 114,604K Shares Outstanding. Its annual sales at the moment are 13,630 K in contrast with the sum of -186,260 K annual income. Company’s last quarter sales were recorded 1,860 K and last quarter income was -52,150 K.
